Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
delavirdine
- Development stage
- Phase 3
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Delavirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with other antiretroviral medications for the treatment of HIV-1 infection. It works by binding directly to viral reverse transcriptase and blocking RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site. This inhibits viral replication, helping to decrease viral load and increase CD4+ cell counts in patients with HIV.
- Brand names
- Rescriptor
- Other names
- delavirdine mesylatedelavirdine mesilate
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on delavirdine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on delavirdine.